# Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo

> **NCT04103060** · PHASE2 · COMPLETED · sponsor: **Dermavant Sciences GmbH** · enrollment: 33 (actual)

## Conditions studied

- Vitiligo

## Interventions

- **DRUG:** Cerdulatinib 0.37% gel
- **DRUG:** Vehicle gel

## Key facts

- **NCT ID:** NCT04103060
- **Lead sponsor:** Dermavant Sciences GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-27
- **Primary completion:** 2020-11-03
- **Final completion:** 2020-11-03
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2020-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04103060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04103060, "Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04103060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*